Allergic Rhinitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age
| Verified date | October 2016 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
| Status | Completed |
| Enrollment | 636 |
| Est. completion date | July 2005 |
| Est. primary completion date | July 2005 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 6 Years to 11 Years |
| Eligibility |
Main Inclusion Criteria: - General good health, other than perennial allergic rhinitis - History and diagnosis of perennial allergic rhinitis by skin prick test - Parent/caregiver must be capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent and comply with all study requirements (visits, record-keeping, etc.) Main Exclusion Criteria: - Participation in any investigational drug trial within the 30 days preceding the Screening Visit or at any time during the trial - Use of any prohibited concomitant medications as defined by the study protocol - Non-vaccinated exposure to, or active infection with, chickenpox or measles within the 21 days preceding the Screening Visit |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Canada | Altana Pharma/Nycomed | Hamilton | |
| Canada | Altana Pharma/Nycomed | Hamilton, ON | |
| Canada | Altana Pharma/Nycomed | Kanata, ON | |
| Canada | Altana Pharma/Nycomed | London | |
| Canada | Altana Pharma/Nycomed | London,ON | |
| Canada | Altana Pharma/Nycomed | Mississauga | |
| Canada | Altana Pharma/Nycomed | Montreal, QC | |
| Canada | Altana Pharma/Nycomed | Niagara Falls | |
| Canada | Altana Pharma/Nycomed | Oshawa, ON | |
| Canada | Altana Pharma/Nycomed | Ottawa | |
| Canada | Altana Pharma/Nycomed | Ottawa, ON | |
| Canada | Altana Pharma/Nycomed | Saskatoon,SK | |
| Canada | Altana Pharma/Nycomed | Ste-Foy PQ | |
| Canada | Altana Pharma/Nycomed | Toronto | |
| Canada | Altana Pharma/Nycomed | Toronto, ON | |
| Canada | Altana Pharma/Nycomed | Winnipeg | |
| United States | Altana Pharma/Nycomed | Atlanta | Georgia |
| United States | Altana Pharma/Nycomed | Austin | Texas |
| United States | Altana Pharma/Nycomed | Brick | New Jersey |
| United States | Altana Pharma/Nycomed | Burke | Virginia |
| United States | Altana Pharma/Nycomed | Canton | Ohio |
| United States | Altana Pharma/Nycomed | Charleston | South Carolina |
| United States | Altana Pharma/Nycomed | Charleston | South Carolina |
| United States | Altana Pharma/Nycomed | Cincinnati, OH | Ohio |
| United States | Altana Pharma/Nycomed | Coral Gables | Florida |
| United States | Altana Pharma/Nycomed | Dubuque | Iowa |
| United States | Altana Pharma/Nycomed | Easton | Pennsylvania |
| United States | Altana Pharma/Nycomed | El Paso | Texas |
| United States | Altana Pharma/Nycomed | Fort Worth | Texas |
| United States | Altana Pharma/Nycomed | Friendswood | Texas |
| United States | Altana Pharma/Nycomed | Gainesville | Georgia |
| United States | Altana Pharma/Nycomed | Hershey | Pennsylvania |
| United States | Altana Pharma/Nycomed | Houston | Texas |
| United States | Altana Pharma/Nycomed | Huntington Beach | California |
| United States | Altana Pharma/Nycomed | Indianapolis | Indiana |
| United States | Altana Pharma/Nycomed | Jefferson City | Missouri |
| United States | Altana Pharma/Nycomed | Katy | Texas |
| United States | Altana Pharma/Nycomed | Liverpool | New York |
| United States | Altana Pharma/Nycomed | Medford | Oregon |
| United States | Altana Pharma/Nycomed | Metairie | Louisiana |
| United States | Altana Pharma/Nycomed | Minneapolis | Minnesota |
| United States | Altana Pharma/Nycomed | Mission Viejo | California |
| United States | Altana Pharma/Nycomed | Moncks Corner | South Carolina |
| United States | Altana Pharma/Nycomed | Newport Beach | California |
| United States | Altana Pharma/Nycomed | Normal | Illinois |
| United States | Altana Pharma/Nycomed | North Dartmouth | Massachusetts |
| United States | Altana Pharma/Nycomed | Ocala | Florida |
| United States | Altana Pharma/Nycomed | Orange | California |
| United States | Altana Pharma/Nycomed | Overland Park | Kansas |
| United States | Altana Pharma/Nycomed | Oxford | Alabama |
| United States | Altana Pharma/Nycomed | Palmdale | California |
| United States | Altana Pharma/Nycomed | Papillion | Nebraska |
| United States | Altana Pharma/Nycomed | Portland | Oregon |
| United States | Altana Pharma/Nycomed | Raleigh | North Carolina |
| United States | Altana Pharma/Nycomed | Richmond | Virginia |
| United States | Altana Pharma/Nycomed | Richmond | Virginia |
| United States | Altana Pharma/Nycomed | Rockville | Maryland |
| United States | Altana Pharma/Nycomed | Rolla, Mo | Missouri |
| United States | Altana Pharma/Nycomed | Salt Lake City | Utah |
| United States | Altana Pharma/Nycomed | San Diego | California |
| United States | Altana Pharma/Nycomed | San Diego | California |
| United States | Altana Pharma/Nycomed | San Jose | California |
| United States | Altana Pharma/Nycomed | Savannah | Georgia |
| United States | Altana Pharma/Nycomed | Shreveport | Louisiana |
| United States | Altana Pharma/Nycomed | Skillman | New Jersey |
| United States | Altana Pharma/Nycomed | South Burlington | Vermont |
| United States | Altana Pharma/Nycomed | Spartanburg | South Carolina |
| United States | Altana Pharma/Nycomed | Spokane | Washington |
| United States | Altana Pharma/Nycomed | St. Louis | Missouri |
| United States | Altana Pharma/Nycomed | Stockton | California |
| United States | Altana Pharma/Nycomed | Sylvania | Ohio |
| United States | Altana Pharma/Nycomed | Upland | Pennsylvania |
| United States | Altana Pharma/Nycomed | Walnut Creek, CA | California |
| United States | Altana Pharma/Nycomed | Wheaton | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
United States, Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | changes in Total Nasal Symptom Score | |||
| Secondary | safety, changes in symptoms |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
| Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
| Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
| Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
| Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
| Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
| Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
| Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
| Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
| Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
| Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 |